Efficacy and activity of treatments after progression from palbociclib plus endocrine therapy in patients with HR+/HER2- metastatic breast cancer: a prospective, monocentric study

• Päätekijät: Raffaella Palumbo (Tekijä), Erica Quaquarini (Tekijä), Giuseppe Saltalamacchia (Tekijä), Alberto Malovini (Tekijä), Pietro Lapidari (Tekijä), Barbara Tagliaferri (Tekijä), Ludovica Mollica (Tekijä), Cristina Maria Teragni (Tekijä), Chiara Barletta (Tekijä), Laura Deborah Locati (Tekijä), Federico Sottotetti (Tekijä)
• Aineistotyyppi: Kirja
• Julkaistu: BioExcel Publishing Ltd, 2024-02-01T00:00:00Z.
• Aiheet: article
• Linkit: Connect to this object online.

Background: Breast cancer is the most frequent tumour worldwide, and the HR+/HER2- subtype is the most common. For this tumour type, endocrine therapy (ET) is the mainstay of treatment. The association of ET and CDK4/6 inhibitors (CDK4/6i) represents the gold standard for first-line or second-line t...